Trump Says Anthropic No Longer Seen as National Security Threat 
John Jumper Leaves Google DeepMind for Anthropic Amid Intensifying AI Talent Race 
BHP Shares Fall as Jansen Potash Project Costs Surge 
US Raises Concerns Over Possible ASML EUV Machine Transfer to China 
Saudi Aramco Explores Sulphur Business Stake Sale to Raise Billions 
Ukrainian Drone Makers Target Japan and Asia Defense Market 
Frank Stronach Found Guilty of Sexual Assault and Indecent Assault in Ontario Court 
Microsoft Taps AWS to Support GitHub Amid AI Coding Boom 
SoftBank Shares Drop as OpenAI Losses and Rising Costs Spark Investor Concerns 
Carro Expands Into Australia With Acquisition of Used-Car Platform CarPlace 
Kingboard Holdings Shares Surge After HK$11.77 Billion Block Trade to Expand PCB and AI Supply Chain Business 
SK Hynix Shares Hit Record High After Shipping Next-Generation HBM4E AI Memory Samples 
Samsung Gains Interest from BYD, Google, AMD as AI Chip Demand Strains TSMC Capacity 
Qantas Nears Launch of World’s Longest Non-Stop Flights to London and New York 
SpaceX Surpasses Amazon in Market Value as Post-IPO Rally Accelerates 
GM and Lockheed Martin Partner to Strengthen U.S. Defense Manufacturing Capacity 
Qantas Unveils Wellness-Focused Nonstop Sydney-London Flights to Reduce Jet Lag 
AMSTERDAM, the Netherlands, Dec. 14, 2015 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, today announced that the Company has been added to the NASDAQ Biotechnology Index® (NBI) as part of NBI's annual selection of biotechnology and pharmaceutical companies listed on the NASDAQ Stock Market® that meet NBI's eligibility criteria. uniQure will be added to the NBI effective prior to market open on December 21, 2015.
The NASDAQ Biotechnology Index is a modified market capitalization weighted index that is designed to track the performance of a set of securities listed on The NASDAQ Stock Market® (NASDAQ®) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark and is re-ranked annually in December. Additional information on the eligibility criteria and further details about the index are available here: https://indexes.nasdaqomx.com/docs/methodology_NBI.pdf
About uniQure
uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with CNS, liver/metabolic and cardiovascular diseases. www.uniQure.com
CONTACT: uniQure:
Aicha Diba
Investor Relations
Direct : +31 20 240 6100
Main: +31 20 566 7394
[email protected]
Media inquiries:
Gretchen Schweitzer
MacDougall Biomedical Communications
Direct: +49 172 861 8540
Main: +49 89 2424 3494 or +1 781 235 3060
[email protected]
